Stay updated on Pembrolizumab + Gemcitabine in UC Subjects Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Gemcitabine in UC Subjects Clinical Trial page.

Latest updates to the Pembrolizumab + Gemcitabine in UC Subjects Clinical Trial page
- CheckyesterdayChange DetectedThe study locations section is updated to include Indiana, Missouri, New Mexico, Ohio, Pennsylvania, and Virginia with a revision tag v3.3.3. The previous location listings and the HHS Vulnerability Disclosure link from the prior revision (v3.3.2) were removed.SummaryDifference0.6%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedRevision: v3.3.2 replaces v3.2.0; no substantive changes to the study details or eligibility are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check37 days agoChange DetectedRemoved a notice about government funding and operating status; study details on the page remain unchanged.SummaryDifference0.3%

- Check51 days agoChange DetectedNo substantive content changes were detected; the page content remains focused on the study details with only minor UI/layout changes and updated timestamps observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check80 days agoChange DetectedMajor update to core page content: adds a government funding notice and current operating status details, plus a version bump to v3.2.0; removes the previous v3.1.0 reference.SummaryDifference2%

- Check87 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive content changes.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab + Gemcitabine in UC Subjects Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Gemcitabine in UC Subjects Clinical Trial page.